APOH Antibody (C_term) Blocking Peptide
- Known as:
- APOH Antibody (C_term) Blocking Peptide
- Catalog number:
- BP7989b
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- APOH Antibody (C_term) Blocking Peptide
Related genes to: APOH Antibody (C_term) Blocking Peptide
- Gene:
- APOH NIH gene
- Name:
- apolipoprotein H
- Previous symbol:
- B2G1
- Synonyms:
- BG
- Chromosome:
- 17q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1987-09-11
- Date modifiied:
- 2015-12-17
Related products to: APOH Antibody (C_term) Blocking Peptide
Related articles to: APOH Antibody (C_term) Blocking Peptide
- Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Angiogenesis drives HCC progression, but reliable biomarkers remain limited. - Source: PubMed
Publication date: 2026/06/20
Zhu ZhanweiGuo CaoShen HongZeng ShanLi Namei - Post-COVID-19 condition (PCC) is often accompanied by endocrine and immune dysregulation. Growth hormone (GH)deficiency has been reported in PCC patients, but its systemic effects remain poorly defined. - Source: PubMed
Publication date: 2026/06/03
Bai GuirongXie XiaominLi ShitingJi WenruiLi HuanHe YantingZhang LiLi LingPei SiqiYang YazhiWu YawenPing Rui - Cannabidiol (CBD) is increasingly being used in veterinary medicine; however, its systemic molecular effects in dogs remain poorly characterized. This study employed label-free quantitative proteomics to compare the serum proteomic responses of healthy dogs ( = 18) after 30 days of oral CBD delivery via three distinct matrices: hemp by-product feed pellets (F), CBD-infused oil (O), and semi-solid treat (SN). The verified chronic doses differed among the groups. Multivariate analysis revealed distinct formulation-specific proteomic signatures, with the F group clustered separately from the O and SN groups. Despite dose and matrix variations, all groups shared a core metabolic response characterized by downregulation of apolipoproteins (APOA4, APOC3, APOC1, and APOH) and upregulation of hemoglobin subunits (HBA and HBB), indicating CBD-mediated modulation of lipid metabolism and redox homeostasis. The high-exposure groups (O, SN) uniquely exhibited upregulation of proteins involved in vascular integrity and tissue scaffolding (e.g., TGFB1, PDGFRB, and VWF), while the SN group also showed induction of immunomodulatory and cytoprotective markers, such as clusterin (CLU). These findings demonstrate that the CBD delivery matrix critically influences systemic bioavailability and the scope of proteomic remodeling. Although all formulations engage core metabolic pathways, high-bioavailability formats induce additional signatures suggestive of vascular stabilization and stress resilience, providing a molecular rationale for optimizing CBD-based therapeutic formulations in canine medicine. - Source: PubMed
Publication date: 2026/05/13
Theerapan WutthiwongLimsuwan SasithornRattanasrisomporn JatupornPloypetch SekkarinTansakul Natthasit - Immune checkpoint inhibitors like pembrolizumab exhibit variable efficacy in metastatic gastric cancer (GC). This study aimed to identify molecular drivers of pembrolizumab response, explore mechanisms of immune checkpoint inhibitors (ICIs) efficacy, and develop a prognostic signature. Transcriptomic analysis of pembrolizumab-treated GC (TIGER database) identified 165 response-associated differentially expressed genes (DEGs). Functional annotation and single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) revealed that responder-upregulated genes (R-DEGs) were enriched in immune activation pathways and mainly localized to CD8 + T/NK cells. In contrast, non-responder-upregulated genes (D-DEGs) were linked to extracellular matrix (ECM) remodeling and mainly expressed in fibroblasts/endothelial cells. CellChat analysis demonstrated that key DEGs mediate immune-stromal crosstalk via MHC-I and collagen/laminin signaling. A prognostic signature (Lasso-StepCox[forward] Riskscore; LSR: APOD, APOH, BATF2, GJA1, MAGED1, SLC5A1, SLCO2A1, VWF, VCAN) was derived and validated in four independent GC cohorts from the GEO and Cancer Genome Atlas (TCGA) database. Multi-omics analyses showed that LSR-high tumors exhibited aggressive clinicopathological features, increased stromal components, reduced cytotoxic immune infiltration, diminished tumor mutational burden (TMB), and poorer prognosis. Immunohistochemistry (IHC) and spatial transcriptomics in GC showed that stromal VWF/VCAN expression correlates with reduced CD8⁺ T cell granzyme B expression, suggesting T cell dysfunction. High VWF expression in GC predicted poor survival, and a combined VWF/VCAN score showed enhanced prognostic stratification. This study highlights stromal-immune crosstalk as a driver of pembrolizumab resistance and provides a signature as a clinical tool for prognosis and personalized therapy in metastatic GC. - Source: PubMed
Publication date: 2026/04/23
Zhang FanZhang QingqingShao ShuaiLi XiaoboCheng YiCao XuYu XiaotangGao Zhengming - The search for new biomarkers that allow an early diagnosis in sepsis has become a necessity in medicine. This study aims to identify protein biomarkers that differentiate sepsis from non-infectious systemic inflammatory response syndrome (NISIRS), addressing the need for early sepsis diagnosis. - Source: PubMed
Publication date: 2026/04/24
Ruiz-Sanmartín AdolfoRibas VicentSuñol DavidChiscano-Camón LuisMartín LauraBajaña IvánBastida JulianaLarrosa NievesGonzález Juan JoséCarrasco María DoloresCanela NúriaFerrer RicardRuiz-Rodríguez Juan Carlos